RVMD
Revolution Medicines, Inc.
Latest Form 4:Sale$11.9MbyCislini Jeff (General Counsel) · filed Aug 25, 2026
Revolution Medicines, Inc. (RVMD) has 65 SEC Form 4 filings (181 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 25, 2026.
The most active filer is See Remarks GOLDSMITH MARK A with 13 filings. Insiders have net sold $83.7M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Mark A. Goldsmith
- Employees:883
- HQ:Redwood City, CA, US
- IPO:2020-02-13
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$116.3M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$44.6B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| General Counsel | Sale | 56,894 | $11.9M | Aug 25 | SEC ↗ | |
| See Remarks | Sale | 86,000 | $18.0M | Aug 25 | SEC ↗ | |
| Director | Sale | 5,580 | $1.0M | Jul 1 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,000 | $3.4M | Jun 26 | SEC ↗ | |
| See Remarks | Sale | 10,020 | $1.6M | Jun 18 | SEC ↗ | |
Anders JackFirst in 3 months | Chief Financial Officer | Sale | 2,722 | $425K | Jun 18 | SEC ↗ |
Cislini JeffFirst in 3 months | General Counsel | Sale | 2,157 | $337K | Jun 18 | SEC ↗ |
| See Remarks | Sale | 4,615 | $720K | Jun 18 | SEC ↗ | |
Kelsey Stephen MichaelFirst in 3 months | See Remarks | Sale | 4,175 | $652K | Jun 18 | SEC ↗ |
| Chief Operating Officer | Sale | 60,400 | $9.7M | Jun 17 | SEC ↗ | |
| Chief Operating Officer | Sale | 3,575 | $558K | Jun 17 | SEC ↗ | |
| Chief Operating Officer | Sale | 29,600 | $4.7M | Jun 17 | SEC ↗ | |
| Chief Operating Officer | Sale | 10,000 | $1.5M | Jun 15 | SEC ↗ | |
| See Remarks | Sale | 3,121 | $481K | May 28 | SEC ↗ | |
| See Remarks | Sale | 3,120 | $413K | Apr 29 | SEC ↗ | |
| See Remarks | Sale | 120,000 | $18.0M | Apr 17 | SEC ↗ | |
Mancini AnthonyFirst filing | See Remarks | Sale | 37,450 | $3.6M | Mar 26 | SEC ↗ |
| General Counsel | Sale | 1,795 | $179K | Mar 19 | SEC ↗ | |
| General Counsel | Sale | 1,163 | $113K | Mar 19 | SEC ↗ | |
| Chief Operating Officer | Sale | 4,583 | $456K | Mar 19 | SEC ↗ | |
Wei LinFirst in 6 months | Chief Medical Officer | Sale | 2,073 | $206K | Mar 19 | SEC ↗ |
Kelsey Stephen MichaelFirst in 3 months | See Remarks | Sale | 4,302 | $428K | Mar 19 | SEC ↗ |
Wang XiaolinFirst filing | See Remarks | Sale | 2,010 | $200K | Mar 19 | SEC ↗ |
| See Remarks | Sale | 12,871 | $1.3M | Mar 19 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,753 | $274K | Mar 19 | SEC ↗ | |
| See Remarks | Sale | 36,000 | $3.6M | Mar 3 | SEC ↗ | |
| General Counsel | Sale | 908 | $105K | Jan 23 | SEC ↗ | |
| Chief Operating Officer | Sale | 75,000 | $7.5M | Jan 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,000 | $980K | Jan 9 | SEC ↗ | |
| See Remarks | Sale | 5,447 | $418K | Dec 18 | SEC ↗ | |
| General Counsel | Sale | 2,688 | $206K | Dec 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,104 | $239K | Dec 18 | SEC ↗ | |
| See Remarks | Sale | 15,394 | $1.2M | Dec 18 | SEC ↗ | |
Horn Margaret AFirst in 3 months | Chief Operating Officer | Sale | 4,847 | $372K | Dec 18 | SEC ↗ |
| See Remarks | Sale | 63,000 | $4.7M | Nov 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 5,418 | $401K | Nov 26 | SEC ↗ | |
| See Remarks | Sale | 20,000 | $1.4M | Nov 20 | SEC ↗ | |
| General Counsel | Sale | 13,388 | $939K | Nov 20 | SEC ↗ | |
| See Remarks | Sale | 20,000 | $1.3M | Nov 14 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,000 | $640K | Nov 13 | SEC ↗ | |
| See Remarks | Sale | 30,000 | $1.8M | Nov 12 | SEC ↗ | |
| See Remarks | Sale | 10,000 | $505K | Oct 20 | SEC ↗ | |
| See Remarks | Sale | 10,000 | $550K | Oct 20 | SEC ↗ | |
| General Counsel | Sale | 12,000 | $660K | Oct 20 | SEC ↗ | |
| See Remarks | Sale | 25,000 | $1.2M | Oct 15 | SEC ↗ | |
| General Counsel | Sale | 1,799 | $80K | Sep 26 | SEC ↗ | |
GOLDSMITH MARK AFirst filing | See Remarks | Sale | 13,411 | $615K | Sep 18 | SEC ↗ |
Horn Margaret AFirst filing | Chief Operating Officer | Sale | 4,775 | $219K | Sep 18 | SEC ↗ |
| See Remarks | Sale | 5,367 | $246K | Sep 18 | SEC ↗ | |
Cislini JeffFirst filing | General Counsel | Sale | 1,869 | $86K | Sep 18 | SEC ↗ |
| Chief Financial Officer | Sale | 2,320 | $106K | Sep 18 | SEC ↗ | |
Wei LinFirst filing | Chief Medical Officer | Sale | 2,160 | $99K | Sep 18 | SEC ↗ |
Kelsey Stephen MichaelFirst filing | See Remarks | Sale | 100,000 | $4.4M | Sep 15 | SEC ↗ |
Kelsey Stephen MichaelFirst filing | See Remarks | Sale | 25,000 | $1.1M | Sep 15 | SEC ↗ |
Anders JackFirst filing | Chief Financial Officer | Sale | 4,762 | $191K | Sep 4 | SEC ↗ |
Anders JackFirst filing | Chief Financial Officer | Sale | 5,238 | $210K | Sep 4 | SEC ↗ |
Related companies
Revolution Medicines, Inc. is in the Healthcare sector.